Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.66 |
| ▸ | BCR | P11274 | 12/20 | 0.66 |
| ▸ | PRKCA | P17252 | 5/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.60 |
| ▸ | EGFR | P00533 | 5/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.56 |
| ▸ | ITK | Q08881 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373707 | 0.85 | ABL1 (0.72) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL16932355 | 0.82 | ABL1 (0.76) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL12320924 | 0.81 | ABL1 (0.78) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL23246315 | 0.81 | ABL1 (0.71) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL6859862 | 0.81 | ABL1 (0.71) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL13437240 | 0.81 | ABL1 (0.73) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL1566168 | 0.80 | ABL1 (0.72) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL2392 | 0.80 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL3210634 | 0.80 | ABL1 (0.75) | ABL1BCRPRKCAPDGFRBPDGFRA | |
| SCHEMBL29366999 | 0.80 | ABL1 (1.00) | ABL1BCRPRKCAPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-1662876-A4 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO INC (US) | 2009-01-14 | — | — | EP | claimed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | claimed |
| JP-2007504230-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1662876-A2 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005020920-A2 | NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | ABL1 13/4885BCR 1042/4885PRKCA 346/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | ABL1 13/4885BCR 1022/4885PRKCA 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.